B3GAT2 and colorectal carcinoma: Ten out of the 12 (83%) multiple tumors and 25 out of the 29 (86.2%) solitary CRC showed hypermethylation of three or more markers from the first panel (i.e. B3GAT2, FOXL2, KCNK13, RAB31, and SLIT1), so they were classified as CIMP tumors.